|1.||Stacker, Steven A: 25 articles (02/2014 - 06/2002)|
|2.||Achen, Marc G: 25 articles (02/2014 - 06/2002)|
|3.||Alitalo, Kari: 23 articles (02/2015 - 01/2002)|
|4.||Ylä-Herttuala, Seppo: 13 articles (01/2014 - 10/2003)|
|5.||Roufail, Sally: 11 articles (08/2013 - 06/2002)|
|6.||Karnezis, Tara: 9 articles (08/2013 - 04/2007)|
|7.||Davydova, Natalia: 6 articles (08/2013 - 04/2007)|
|8.||Shayan, Ramin: 6 articles (08/2013 - 10/2011)|
|9.||Baldwin, Megan E: 6 articles (05/2013 - 06/2002)|
|10.||Paavonen, Karri: 6 articles (03/2013 - 01/2002)|
|1.||Neoplasm Metastasis (Metastasis)
06/01/2004 - "These data suggest that targeting VEGF D and flt-4t(Delta773-1081) receptors may be particularly effective in the prevention of lymph node metastases."
02/01/2003 - "The purpose of this study is to determine whether VEGF-D correlates with lymph node metastasis or prognosis. "
01/01/2015 - "VEGF-D is a potential predictive marker of positive lymph node metastasis in cN0 patients."
01/01/2015 - "In cases with lymph node metastasis, the VEGF-D-expression score was significantly higher than in those without lymph node metastasis (p = 0.0006). "
01/01/2015 - "High VEGF-D and low MMP-2 serum levels predict LN metastasis in patients with UCB at the time of RC. "
03/01/2012 - "The definition of the structure of the complex of VEGF-D bound to its receptors would be beneficial for design of inhibitors of VEGF-D signaling aimed at restricting the growth and spread of cancer. "
04/30/2009 - "Vascular endothelial growth factor-D transgenic mice show enhanced blood capillary density, improved postischemic muscle regeneration, and increased susceptibility to tumor formation."
12/01/2012 - "In this study, we developed an anti-VEGF-D monoclonal antibody, cVE199, and investigated its in vitro properties, in vivo effects against tumors and possible target indications to evaluate its potential as a therapeutic antibody. "
01/01/2015 - "In tumor budding regions VEGF-D-induced receptor activation by autophosphorylation at Tyr1214 seems to be a possible initial event of the VEGFR-2-mediated signaling pathway, but without effect on metastatic behaviour. "
12/01/2014 - "Cancer cell proliferation, lymphangiogenesis, and expression levels of VEGF-D, COX-2, and MMP-2 played important roles in these HO-1-related effects. "
|3.||Breast Neoplasms (Breast Cancer)
02/01/2003 - "VEGF-D may be useful in the treatment of breast cancer as a decision-making biomarker for aggressive treatment after operation."
03/01/2005 - "These findings suggest that VEGF-D functions both as an autocrine growth factor and a stimulator of angiogenesis in breast cancer."
03/01/2005 - "VEGF-D and HIF-1alpha in breast cancer."
02/01/2003 - "Whether VEGF-D expression plays prognostic role in breast cancer was also investigated. "
02/01/2003 - "VEGF-D expression is associated with lymph node metastasis and may be a novel prognostic factor in breast cancer. "
|4.||Stomach Neoplasms (Stomach Cancer)
01/01/2014 - "STAT3 regulation the expression of VEGF-D in HGC-27 gastric cancer cell."
10/01/2013 - "VEGF-D is the only marker that can be regarded as an unfavorable prognostic indicator for patients with advanced gastric cancer."
10/01/2012 - "VEGF-D is an unfavorable indicator of OS (HR = 1.68, 95 % CI: 1.02-2.34) and DFS (HR = 1.88, 95 % CI: 1.07-2.70) in patients with gastric cancer. "
05/01/2011 - "VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery."
08/01/2008 - "VEGF-D expression was observed in 62.5% of the gastric cancers and in 9.6% of the non-neoplastic gastric tissue. "
11/01/2015 - "Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis."
08/01/2013 - "Serum VEGF-D is a biologically plausible and useful biomarker in lymphangioleiomyomatosis that correlates with disease severity and treatment response. "
09/01/2010 - "Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases."
05/01/2009 - "Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement."
01/10/2008 - "Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis."
|1.||Vascular Endothelial Growth Factor C
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Vascular Endothelial Growth Factor Receptor-3 (Flt 4)
|6.||platelet-derived growth factor A
|7.||Messenger RNA (mRNA)
|8.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|9.||Vascular Endothelial Growth Factor D
|10.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)